| 301.31 Delayed Data As of Oct 22 |  +3.32 / +1.11%Today’s Change | 271.37 Today|||52-Week Range 442.00 | -19.33% Year-to-Date |
| Here's Why Dermira Stock Is Rocketing Higher Today Oct 18 / MotleyFool.com - Paid Partner Content | Are These 3 Beaten-Down Biotech Stocks Bargains Now? Oct 17 / MotleyFool.com - Paid Partner Content |
| Previous close | 297.99 |
| Today’s open | 305.00 |
| Day’s range | 301.20 - 306.93 |
| Volume | 729,069 |
| Average volume (3 months) | 755,407 |
| Market cap | $32.3B |
| Earnings growth (last year) | +100.98% |
| Earnings growth (this year) | +2.17% |
| Earnings growth (next 5 years) | +8.00% |
| Revenue growth (last year) | +14.28% |
| P/E ratio | 16.7 |
| Price/Sales | 6.39 |
| Price/Book | 3.73 |
| Today’s change | Today’s % change | |
|---|---|---|
| ALXNAlexion Pharmaceutic... | -1.45 | -1.44% |
| VRTXVertex Pharmaceutica... | +7.53 | +4.10% |
| SGENSeattle Genetics Inc | -2.25 | -2.23% |
| INCYIncyte Corp | -0.08 | -0.10% |
| Next reporting date | November 5, 2019 |
| EPS forecast (this quarter) | $6.35 |
| Annual revenue (last year) | $6.7B |
| Annual profit (last year) | $2.4B |
| Net profit margin | 36.42% |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Tarrytown, New York |
